- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00327691
Uno studio per determinare il grado di ulteriore riduzione del rischio CV nell'abbassamento delle LDL al di sotto dei livelli minimi target (TNT)
1 maggio 2007 aggiornato da: Pfizer
L'effetto del colesterolo LDL, abbassamento oltre gli obiettivi minimi attualmente raccomandati sulla recidiva di malattia coronarica (CHD) in pazienti con CHD preesistente
L'obiettivo principale di questo studio è determinare il grado di ulteriore riduzione del rischio cardiovascolare che è stato accumulato dai pazienti abbassando il loro LDL-C oltre il livello target minimo attualmente accettato per i pazienti con CHD preesistente.
Gli obiettivi secondari includono il profilo di sicurezza di questa strategia di trattamento, il suo rapporto costo-efficacia, l'effetto su altri eventi e procedure correlati all'aterosclerosi e la mortalità totale.
Panoramica dello studio
Stato
Completato
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione
8600
Fase
- Fase 4
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
St. Leonards, New South Wales, Australia, 2065
- Pfizer Investigational Site
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Pfizer Investigational Site
-
Brisbane, Queensland, Australia, 4029
- Pfizer Investigational Site
-
Chermside, Queensland, Australia, 4032
- Pfizer Investigational Site
-
Greenslopes, Queensland, Australia, 4130
- Pfizer Investigational Site
-
Herston, Queensland, Australia, 4029
- Pfizer Investigational Site
-
Milton, Queensland, Australia, 4064
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Pfizer Investigational Site
-
Bedford Park, South Australia, Australia, 5042
- Pfizer Investigational Site
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Pfizer Investigational Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Pfizer Investigational Site
-
Parkville, Victoria, Australia, 3050
- Pfizer Investigational Site
-
Prahran, Victoria, Australia, 3181
- Pfizer Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Pfizer Investigational Site
-
-
-
-
-
Feldkirch, Austria, A-6807
- Pfizer Investigational Site
-
Oberpullendorf, Austria, A-7350
- Pfizer Investigational Site
-
Wien, Austria, A-1090
- Pfizer Investigational Site
-
Wien, Austria, 1100
- Pfizer Investigational Site
-
-
-
-
-
Aalst, Belgio, 9300
- Pfizer Investigational Site
-
Antwerpen, Belgio, B-2020
- Pfizer Investigational Site
-
Genk, Belgio, 3600
- Pfizer Investigational Site
-
Genk, Belgio, B-3600
- Pfizer Investigational Site
-
Godinne, Belgio, 5530
- Pfizer Investigational Site
-
Leuven, Belgio, 3000
- Pfizer Investigational Site
-
Lommel, Belgio, 3920
- Pfizer Investigational Site
-
Neerpelt, Belgio, 3910
- Pfizer Investigational Site
-
-
-
-
-
Quebec, Canada, G1R 2J6
- Pfizer Investigational Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2E 7C5
- Pfizer Investigational Site
-
Calgary, Alberta, Canada, T2N 4N1
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T5R 4H5
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T6G 2B7
- Pfizer Investigational Site
-
-
British Columbia
-
Nanaimo, British Columbia, Canada, V9S 2B8
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canada, V6R 1Y6
- Pfizer Investigational Site
-
Victoria, British Columbia, Canada, V8T 5G4
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Pfizer Investigational Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Pfizer Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Pfizer Investigational Site
-
London, Ontario, Canada, N6A 4G5
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1Y 4W7
- Pfizer Investigational Site
-
Sudbury, Ontario, Canada, P3E 1B8
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M5C 2T2
- Pfizer Investigational Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 5H6
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3A 1A1
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H1T 1C8
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H2W 1R7
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Pfizer Investigational Site
-
St-foy, Quebec, Canada, G1V 4G2
- Pfizer Investigational Site
-
-
-
-
-
Agen, Francia, 47000
- Pfizer Investigational Site
-
Bordeaux, Francia, 33000
- Pfizer Investigational Site
-
Brest, Francia, 29200
- Pfizer Investigational Site
-
Clermont-ferrand, Francia, 63003
- Pfizer Investigational Site
-
Lyon, Francia, 69003
- Pfizer Investigational Site
-
Marseille, Francia, 13915 Cedex 20
- Pfizer Investigational Site
-
Paris CEDEX 05, Francia, 75230
- Pfizer Investigational Site
-
Rennes, Francia, 35033
- Pfizer Investigational Site
-
Roubaix Cdx, Francia, 59056
- Pfizer Investigational Site
-
Strasbourg, Francia, 67091
- Pfizer Investigational Site
-
Toulouse, Francia, 31059
- Pfizer Investigational Site
-
Toulouse, Francia, 31400
- Pfizer Investigational Site
-
-
Cedex
-
Pessac, Cedex, Francia, 33604
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Germania, 13353
- Pfizer Investigational Site
-
Berlin, Germania, 13439
- Pfizer Investigational Site
-
Essen, Germania, 45329
- Pfizer Investigational Site
-
Hamburg, Germania, 20246
- Pfizer Investigational Site
-
Schwerte, Germania, D-58239
- Pfizer Investigational Site
-
Tostedt, Germania, 21255
- Pfizer Investigational Site
-
Wurzburg, Germania, 97070
- Pfizer Investigational Site
-
-
-
-
-
Cork, Irlanda
- Pfizer Investigational Site
-
Dublin, Irlanda, D8
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italia, 40138
- Pfizer Investigational Site
-
Bologna, Italia, 40139
- Pfizer Investigational Site
-
Cuneo, Italia, 12100
- Pfizer Investigational Site
-
Firenze, Italia, 50134
- Pfizer Investigational Site
-
Napoli, Italia, 80131
- Pfizer Investigational Site
-
Rome, Italia, 00184
- Pfizer Investigational Site
-
Udine, Italia, 33100
- Pfizer Investigational Site
-
-
-
-
-
's-Hertogenbosch, Olanda, 5211 NL
- Pfizer Investigational Site
-
Alkmaar, Olanda, 1815 JD
- Pfizer Investigational Site
-
Amersfoort, Olanda, 3818 ES
- Pfizer Investigational Site
-
Amsterdam, Olanda, 1105 AZ
- Pfizer Investigational Site
-
Breda, Olanda, 4818 CK
- Pfizer Investigational Site
-
Eindhoven, Olanda, 5623 EJ
- Pfizer Investigational Site
-
Enschede, Olanda, 7513 ER
- Pfizer Investigational Site
-
Groningen, Olanda, 9713 GZ
- Pfizer Investigational Site
-
Groningen, Olanda, 9728 NZ
- Pfizer Investigational Site
-
Leiden, Olanda, 2333 ZA
- Pfizer Investigational Site
-
Nieuwegein, Olanda, 3435 CM
- Pfizer Investigational Site
-
Nijmegen, Olanda, 6532 SZ
- Pfizer Investigational Site
-
Zwolle, Olanda, 8011 JW
- Pfizer Investigational Site
-
Zwolle, Olanda, 8025 AB
- Pfizer Investigational Site
-
-
-
-
-
Barnet, Regno Unito, EN5 3DJ
- Pfizer Investigational Site
-
Glasgow, Regno Unito, G11 6NT
- Pfizer Investigational Site
-
London, Regno Unito, E1 1BB
- Pfizer Investigational Site
-
London, Regno Unito, NW3 2PF
- Pfizer Investigational Site
-
Paisley, Regno Unito, P1 1HR
- Pfizer Investigational Site
-
-
Essex
-
Romford, Essex, Regno Unito, RM7 OBE
- Pfizer Investigational Site
-
-
Greater London
-
London, Greater London, Regno Unito, E2 9JX
- Pfizer Investigational Site
-
London, Greater London, Regno Unito, NW10 7NS
- Pfizer Investigational Site
-
London, Greater London, Regno Unito, SW17 0RE
- Pfizer Investigational Site
-
-
Hampshire
-
Aldershot, Hampshire, Regno Unito, GU11 3RB
- Pfizer Investigational Site
-
-
Kent
-
Farnborough, Kent, Regno Unito, BR6 7AR
- Pfizer Investigational Site
-
-
Lancashire
-
Blackpool, Lancashire, Regno Unito, FY3 8NR
- Pfizer Investigational Site
-
-
Leicestershire
-
Leicester, Leicestershire, Regno Unito, LE3 9QP
- Pfizer Investigational Site
-
-
Middlesex
-
London, Middlesex, Regno Unito, HA8 0AD
- Pfizer Investigational Site
-
-
West Midlands
-
Coventry, West Midlands, Regno Unito, CV1 4FH
- Pfizer Investigational Site
-
Coventry, West Midlands, Regno Unito, CV2 2DX
- Pfizer Investigational Site
-
-
Wiltshire
-
Swindon, Wiltshire, Regno Unito, SN3 6BB
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spagna, 08035
- Pfizer Investigational Site
-
Barcelona, Spagna, 08036
- Pfizer Investigational Site
-
Cordoba, Spagna, 14004
- Pfizer Investigational Site
-
Madrid, Spagna, 28007
- Pfizer Investigational Site
-
Madrid, Spagna, 28041
- Pfizer Investigational Site
-
Madrid, Spagna, 28029
- Pfizer Investigational Site
-
Madrid, Spagna, 28040
- Pfizer Investigational Site
-
San Sebastian, Spagna, 20014
- Pfizer Investigational Site
-
Santiago de Compostela, Spagna, 15706
- Pfizer Investigational Site
-
Sevilla, Spagna, 41013
- Pfizer Investigational Site
-
Sevilla, Spagna, 41009
- Pfizer Investigational Site
-
Valladolid, Spagna, 47011
- Pfizer Investigational Site
-
Zaragoza, Spagna, 50009
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Alabaster, Alabama, Stati Uniti, 35007
- Pfizer Investigational Site
-
Birmingham, Alabama, Stati Uniti, 35205-4785
- Pfizer Investigational Site
-
Birmingham, Alabama, Stati Uniti, 35213
- Pfizer Investigational Site
-
Birmingham, Alabama, Stati Uniti, 35294-2041
- Pfizer Investigational Site
-
Hoover, Alabama, Stati Uniti, 35216
- Pfizer Investigational Site
-
Montgomery, Alabama, Stati Uniti, 36117
- Pfizer Investigational Site
-
-
Arizona
-
Mesa, Arizona, Stati Uniti, 85202
- Pfizer Investigational Site
-
Mesa, Arizona, Stati Uniti, 85206
- Pfizer Investigational Site
-
-
California
-
Burbank, California, Stati Uniti, 91505
- Pfizer Investigational Site
-
Camp Pendleton, California, Stati Uniti, 92055
- Pfizer Investigational Site
-
Fresno, California, Stati Uniti, 93703
- Pfizer Investigational Site
-
La Jolla, California, Stati Uniti, 92037
- Pfizer Investigational Site
-
Loma Linda, California, Stati Uniti, 92354
- Pfizer Investigational Site
-
Los Angeles, California, Stati Uniti, 90048
- Pfizer Investigational Site
-
Los Angeles, California, Stati Uniti, 90017-2395
- Pfizer Investigational Site
-
Modesto, California, Stati Uniti, 95350
- Pfizer Investigational Site
-
Pasadena, California, Stati Uniti, 91105
- Pfizer Investigational Site
-
Rancho Mirage, California, Stati Uniti, 92270
- Pfizer Investigational Site
-
San Diego, California, Stati Uniti, 92134-3303
- Pfizer Investigational Site
-
San Francisco, California, Stati Uniti, 94143-0130
- Pfizer Investigational Site
-
San Francisco, California, Stati Uniti, 94143-0326
- Pfizer Investigational Site
-
Santa Rosa, California, Stati Uniti, 95403
- Pfizer Investigational Site
-
Stanford, California, Stati Uniti
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Pfizer Investigational Site
-
Denver, Colorado, Stati Uniti, 80220
- Pfizer Investigational Site
-
Denver, Colorado, Stati Uniti, 80218
- Pfizer Investigational Site
-
Denver, Colorado, Stati Uniti, 80203
- Pfizer Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, Stati Uniti, 06610
- Pfizer Investigational Site
-
Hartford, Connecticut, Stati Uniti, 06102
- Pfizer Investigational Site
-
New Britain, Connecticut, Stati Uniti, 06053
- Pfizer Investigational Site
-
-
Delaware
-
Newark, Delaware, Stati Uniti, 19718
- Pfizer Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20037
- Pfizer Investigational Site
-
-
Florida
-
Clearwater, Florida, Stati Uniti, 33756
- Pfizer Investigational Site
-
Gainsville, Florida, Stati Uniti, 32608
- Pfizer Investigational Site
-
Gainsville, Florida, Stati Uniti, 32610
- Pfizer Investigational Site
-
Hollywood, Florida, Stati Uniti, 33021
- Pfizer Investigational Site
-
Inverness, Florida, Stati Uniti, 34452
- Pfizer Investigational Site
-
Lakeland, Florida, Stati Uniti, 33805
- Pfizer Investigational Site
-
Miami, Florida, Stati Uniti, 33173
- Pfizer Investigational Site
-
Miami, Florida, Stati Uniti, 33176
- Pfizer Investigational Site
-
Ocala, Florida, Stati Uniti, 34474
- Pfizer Investigational Site
-
Orlando, Florida, Stati Uniti, 32803
- Pfizer Investigational Site
-
Port Charlotte, Florida, Stati Uniti, 33952
- Pfizer Investigational Site
-
Sarasota, Florida, Stati Uniti, 34239
- Pfizer Investigational Site
-
Stuart, Florida, Stati Uniti, 34996
- Pfizer Investigational Site
-
Tamarac, Florida, Stati Uniti, 33321
- Pfizer Investigational Site
-
The Villages, Florida, Stati Uniti, 32159
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30309
- Pfizer Investigational Site
-
Canton, Georgia, Stati Uniti, 30114
- Pfizer Investigational Site
-
-
Illinois
-
Berwyn, Illinois, Stati Uniti, 60402
- Pfizer Investigational Site
-
Blue Island, Illinois, Stati Uniti, 60406
- Pfizer Investigational Site
-
Chicago, Illinois, Stati Uniti, 60611
- Pfizer Investigational Site
-
Chicago, Illinois, Stati Uniti, 60610
- Pfizer Investigational Site
-
DuQuoin, Illinois, Stati Uniti, 62832
- Pfizer Investigational Site
-
Evanston, Illinois, Stati Uniti, 60201
- Pfizer Investigational Site
-
Lake Forest, Illinois, Stati Uniti, 60045
- Pfizer Investigational Site
-
Marion, Illinois, Stati Uniti, 62959
- Pfizer Investigational Site
-
Pekin, Illinois, Stati Uniti, 61554
- Pfizer Investigational Site
-
Peoria, Illinois, Stati Uniti, 61603
- Pfizer Investigational Site
-
Peoria, Illinois, Stati Uniti, 61614
- Pfizer Investigational Site
-
-
Indiana
-
Beech Grove, Indiana, Stati Uniti, 46107
- Pfizer Investigational Site
-
Evansville, Indiana, Stati Uniti, 47710
- Pfizer Investigational Site
-
Fort Wayne, Indiana, Stati Uniti, 46805
- Pfizer Investigational Site
-
Fort Wayne, Indiana, Stati Uniti, 46825
- Pfizer Investigational Site
-
Jeffersonville, Indiana, Stati Uniti, 47130
- Pfizer Investigational Site
-
Scottsburg, Indiana, Stati Uniti, 47170
- Pfizer Investigational Site
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50314
- Pfizer Investigational Site
-
Iowa City, Iowa, Stati Uniti, 52242
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160-7200
- Pfizer Investigational Site
-
Lathe, Kansas, Stati Uniti, 66061
- Pfizer Investigational Site
-
Overland Park, Kansas, Stati Uniti, 66213
- Pfizer Investigational Site
-
Wichita, Kansas, Stati Uniti, 67220
- Pfizer Investigational Site
-
-
Kentucky
-
Edgewood, Kentucky, Stati Uniti, 41017
- Pfizer Investigational Site
-
Erlanger, Kentucky, Stati Uniti, 41018
- Pfizer Investigational Site
-
Louisville, Kentucky, Stati Uniti, 40202
- Pfizer Investigational Site
-
-
Louisiana
-
Marrero, Louisiana, Stati Uniti, 70072
- Pfizer Investigational Site
-
New Orleans, Louisiana, Stati Uniti, 70112
- Pfizer Investigational Site
-
New Orleans, Louisiana, Stati Uniti, 70121
- Pfizer Investigational Site
-
-
Maine
-
Portland, Maine, Stati Uniti, 04102
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21218
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21205
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21287
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21201
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21204
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21208
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21224
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21228
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21229
- Pfizer Investigational Site
-
Baltimore, Maryland, Stati Uniti, 21237
- Pfizer Investigational Site
-
Bel Air, Maryland, Stati Uniti, 21014
- Pfizer Investigational Site
-
Westminster, Maryland, Stati Uniti, 21157
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Pfizer Investigational Site
-
Boston, Massachusetts, Stati Uniti, 02215
- Pfizer Investigational Site
-
Burlington, Massachusetts, Stati Uniti, 1805
- Pfizer Investigational Site
-
-
Michigan
-
Dearborn, Michigan, Stati Uniti, 48126
- Pfizer Investigational Site
-
Detroit, Michigan, Stati Uniti, 48202
- Pfizer Investigational Site
-
Farmington Hill, Michigan, Stati Uniti, 48336
- Pfizer Investigational Site
-
Sterling Heights, Michigan, Stati Uniti, 48310
- Pfizer Investigational Site
-
West Bloomfield, Michigan, Stati Uniti, 48322
- Pfizer Investigational Site
-
-
Minnesota
-
Duluth, Minnesota, Stati Uniti, 55805
- Pfizer Investigational Site
-
Edina, Minnesota, Stati Uniti, 55435
- Pfizer Investigational Site
-
Maplewood, Minnesota, Stati Uniti, 55109
- Pfizer Investigational Site
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Pfizer Investigational Site
-
St. Paul, Minnesota, Stati Uniti, 55102
- Pfizer Investigational Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Pfizer Investigational Site
-
St. Louis, Missouri, Stati Uniti, 63110
- Pfizer Investigational Site
-
St. Louis, Missouri, Stati Uniti, 63141
- Pfizer Investigational Site
-
St. Louis, Missouri, Stati Uniti, 63104
- Pfizer Investigational Site
-
St. Louis, Missouri, Stati Uniti, 63110-0205
- Pfizer Investigational Site
-
St. Louis, Missouri, Stati Uniti, 63117
- Pfizer Investigational Site
-
-
Nebraska
-
Papillion, Nebraska, Stati Uniti, 68046
- Pfizer Investigational Site
-
-
New Hampshire
-
Manchester, New Hampshire, Stati Uniti, 03102
- Pfizer Investigational Site
-
-
New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Pfizer Investigational Site
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Pfizer Investigational Site
-
Brooklyn, New York, Stati Uniti, 11203
- Pfizer Investigational Site
-
Hawthorne, New York, Stati Uniti, 10535
- Pfizer Investigational Site
-
Manlius, New York, Stati Uniti, 13104
- Pfizer Investigational Site
-
New York, New York, Stati Uniti, 10021
- Pfizer Investigational Site
-
New York, New York, Stati Uniti, 10029
- Pfizer Investigational Site
-
New York, New York, Stati Uniti, 10032
- Pfizer Investigational Site
-
Rochester, New York, Stati Uniti, 14618
- Pfizer Investigational Site
-
Rochester, New York, Stati Uniti, 14607
- Pfizer Investigational Site
-
Rochester, New York, Stati Uniti, 14621
- Pfizer Investigational Site
-
Syracuse, New York, Stati Uniti, 13202
- Pfizer Investigational Site
-
Syracuse, New York, Stati Uniti, 13210
- Pfizer Investigational Site
-
Valhalla, New York, Stati Uniti, 10595
- Pfizer Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28803
- Pfizer Investigational Site
-
Durham, North Carolina, Stati Uniti, 27710
- Pfizer Investigational Site
-
Eden, North Carolina, Stati Uniti, 27288
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Pfizer Investigational Site
-
-
Ohio
-
Beachwood, Ohio, Stati Uniti, 44122
- Pfizer Investigational Site
-
Cincinnati, Ohio, Stati Uniti, 45219
- Pfizer Investigational Site
-
Cincinnati, Ohio, Stati Uniti, 45229
- Pfizer Investigational Site
-
Cincinnati, Ohio, Stati Uniti, 45246
- Pfizer Investigational Site
-
Cleveland, Ohio, Stati Uniti, 44106-5038
- Pfizer Investigational Site
-
Cleveland, Ohio, Stati Uniti, 44195
- Pfizer Investigational Site
-
Columbus, Ohio, Stati Uniti, 43210
- Pfizer Investigational Site
-
Columbus, Ohio, Stati Uniti, 43221
- Pfizer Investigational Site
-
Kettering, Ohio, Stati Uniti, 45429-1221
- Pfizer Investigational Site
-
Lorain, Ohio, Stati Uniti, 44053
- Pfizer Investigational Site
-
Sandusky, Ohio, Stati Uniti, 44870
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Stati Uniti, 74133
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Stati Uniti, 74136-1920
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Stati Uniti, 74136
- Pfizer Investigational Site
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- Pfizer Investigational Site
-
Portland, Oregon, Stati Uniti, 97210
- Pfizer Investigational Site
-
Portland, Oregon, Stati Uniti, 97216
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18102
- Pfizer Investigational Site
-
Allentown, Pennsylvania, Stati Uniti, 18106-0880
- Pfizer Investigational Site
-
Lansdale, Pennsylvania, Stati Uniti, 19446
- Pfizer Investigational Site
-
Lehighton, Pennsylvania, Stati Uniti, 18235
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- Pfizer Investigational Site
-
Sellersville, Pennsylvania, Stati Uniti, 18960
- Pfizer Investigational Site
-
-
Rhode Island
-
Pawtucket, Rhode Island, Stati Uniti, 02860
- Pfizer Investigational Site
-
Providence, Rhode Island, Stati Uniti, 02906
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29403
- Pfizer Investigational Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Pfizer Investigational Site
-
Sioux Falls, South Dakota, Stati Uniti, 57108
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38104
- Pfizer Investigational Site
-
Memphis, Tennessee, Stati Uniti, 38105
- Pfizer Investigational Site
-
Memphis, Tennessee, Stati Uniti, 38119-5209
- Pfizer Investigational Site
-
Memphis, Tennessee, Stati Uniti, 38128
- Pfizer Investigational Site
-
Nashville, Tennessee, Stati Uniti, 37205
- Pfizer Investigational Site
-
Nashville, Tennessee, Stati Uniti, 37232-6300
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78756
- Pfizer Investigational Site
-
Dallas, Texas, Stati Uniti, 75246
- Pfizer Investigational Site
-
Dallas, Texas, Stati Uniti, 75235
- Pfizer Investigational Site
-
Dallas, Texas, Stati Uniti, 75390-9047
- Pfizer Investigational Site
-
Denton, Texas, Stati Uniti, 76204
- Pfizer Investigational Site
-
Houston, Texas, Stati Uniti, 77030
- Pfizer Investigational Site
-
Lackland AFB, Texas, Stati Uniti, 78236-5300
- Pfizer Investigational Site
-
San Antonio, Texas, Stati Uniti, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84124
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- Pfizer Investigational Site
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23249
- Pfizer Investigational Site
-
Richmond, Virginia, Stati Uniti, 23298
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53295
- Pfizer Investigational Site
-
-
-
-
-
Bloemfontein, Sud Africa, 9301
- Pfizer Investigational Site
-
Cape Town, Sud Africa, 7500
- Pfizer Investigational Site
-
Cape Town, Sud Africa, 7405
- Pfizer Investigational Site
-
Parow, Sud Africa, 7505
- Pfizer Investigational Site
-
-
Gauteng
-
Johannesburg, Gauteng, Sud Africa, 2193
- Pfizer Investigational Site
-
Sunninghill, Gauteng, Sud Africa, 2157
- Pfizer Investigational Site
-
-
-
-
-
Bern, Svizzera, 3010
- Pfizer Investigational Site
-
Geneve 14, Svizzera, CH-1211
- Pfizer Investigational Site
-
Lausanne, Svizzera, CH-1011
- Pfizer Investigational Site
-
Lugano, Svizzera, 6900
- Pfizer Investigational Site
-
St Gallen, Svizzera, CH-9007
- Pfizer Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 35 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Criterio di inclusione:
Uomini e donne di età compresa tra 35 e 75 anni con malattia coronarica evidente
Criteri di esclusione:
Ipersensibilità nota alla terapia con HMG CO-A reduttasi, malattia epatica, evidenza di iperlipidemia secondaria
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
|---|
|
L'esito primario è il tempo di occorrenza di un maggiore
|
|
evento cardiovascolare, definito come l'esito composito della
|
|
seguenti endpoint clinici
|
|
Morte CHD
|
|
IM non fatale/non correlato alla procedura
|
|
Arresto cardiaco rianimato o ictus fatale/non fatale
|
Misure di risultato secondarie
Misura del risultato |
|---|
|
Il verificarsi dei seguenti eventi clinici
|
|
Evento coronarico maggiore (morte CHD, infarto miocardico non fatale o arresto cardiaco rianimato)
|
|
qualsiasi evento coronarico (evento coronarico maggiore o CABG
|
|
PTCA, altra procedura di rivascolarizzazione, infarto del miocardio correlato alla procedura o angina documentata)
|
|
evento cerebrovascolare (ictus fatale o non fatale, TIA)
|
|
malattia vascolare periferica; ricovero con diagnosi primaria di CHF
|
|
qualsiasi evento cardiovascolare (uno dei precedenti); e mortalità per tutte le cause.
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17.
- Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
- Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.
- Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.
- Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.
- Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.
- Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
- Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148.
- Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
- Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
- Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.
- Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014.
- Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
- Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
- Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043.
- Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29.
- Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. doi: 10.1161/CIRCGENETICS.111.960252. Epub 2011 Dec 1.
- Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052.
- Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
- Waters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502. doi: 10.1016/j.pcad.2009.01.001.
- Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug;83(8):870-9.
- Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.
- Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 aprile 1998
Completamento primario
7 dicembre 2022
Completamento dello studio
1 agosto 2004
Date di iscrizione allo studio
Primo inviato
16 maggio 2006
Primo inviato che soddisfa i criteri di controllo qualità
16 maggio 2006
Primo Inserito (Stima)
18 maggio 2006
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
3 maggio 2007
Ultimo aggiornamento inviato che soddisfa i criteri QC
1 maggio 2007
Ultimo verificato
1 maggio 2007
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Arteriosclerosi
- Malattie arteriose occlusive
- Malattie cardiache
- Ictus
- Disfunsione dell'arteria coronaria
- Ischemia miocardica
- Malattia coronarica
- Malattia cardiovascolare
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Antimetaboliti
- Agenti anticolesteremici
- Agenti ipolipidemizzanti
- Agenti regolatori dei lipidi
- Inibitori dell'idrossimetilglutaril-CoA reduttasi
- Atorvastatina
Altri numeri di identificazione dello studio
- 0981-117
- A2581136
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .